24
total announcements
544210.BO · 15 min delayed
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has dispatched a letter to members whose email addresses are not registered with the company or depository participants, providing a web-link to the Annual Report 2025-26 and Notice of 45th Annual General Meeting.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced a schedule for an investor meet on September 04, 2026, with a group of institutional investors in Pune. The meeting is subject to change due to exigencies and no unpublished price-sensitive information will be shared.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has reaffirmed its credit ratings by CARE Ratings Limited, citing the company's healthy business risk profile, diversified revenue base, leadership position, and well-established R&D capabilities.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has published a newspaper advertisement for its 45th Annual General Meeting (AGM) and e-voting information, to be held on September 21, 2026, through video conferencing or other audio-visual means.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has released its Business Responsibility and Sustainability Report for the Financial Year 2025-26, highlighting its commitment to responsible business practices, sustainable growth, and creating long-term value for stakeholders.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the notice of its 45th Annual General Meeting (AGM) to be held on September 21, 2026, through video conferencing. The AGM will consider the annual report for the financial year 2025-26 and other business.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced its Annual Report for the Financial Year 2025-26, including the Notice of the 45th Annual General Meeting, scheduled to be held on September 21, 2026.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has allotted 19,100 equity shares to eligible employees under the Emcure - Employee Stock Option Scheme 2013, increasing the issued and paid-up share capital to Rs.1,89,69,92,470.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd announced the transcript of their Q1 FY27 earnings call, with the CEO Satish Mehta discussing the company's performance and organizational updates, including the appointment of a new Chairman and the promotion of Samit Mehta as Chief Operating Officer.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has received the Establishment Inspection Report (EIR) from the USFDA, with the inspection status classified as Voluntary Action Indicated (VAI) and the inspection standing closed.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the schedule of participation in Investor Conferences by its officials, including Emkay 'Confluence 2026', Motilal Oswal 22nd Annual Global Investor Conference, Elara India Dialogue 2026, Kotak Healthcare Forum 2026, and 11th Annual J.P. Morgan India Conference.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the schedule of Analyst/ Investor Meetings to be held between August 12, 2026, and September 22, 2026, in various cities across India. The meetings are part of the company's efforts to engage with investors and analysts.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the schedule of analyst/investor meetings to be held in August and September 2026, including participation in various conferences and one-on-one meetings with investors.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the schedule of Analyst/ Investor Meetings to be held from August 12, 2026, to September 22, 2026, in various cities across India. The meetings are part of the company's efforts to engage with investors and analysts.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the schedule of participation in investor conferences by its officials, including Emkay 'Confluence 2026', Motilal Oswal 22nd Annual Global Group and Investor Conference, Elara India Dialogue 2026, Kotak Healthcare Forum 2026, and 11th Annual J.P. Morgan India Conference.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has published unaudited financial results for the quarter ended June 30, 2026, in newspapers and on its website.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has made available the audio recording of its Q1 FY27 earnings call on its website.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the date of its 45th Annual General Meeting and the record date for payment of final dividend for the financial year ended March 31, 2026.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced changes in its Board of Directors, with Mr. Berjis Desai resigning as Chairman and Non-Executive Director, and Mr. Raghu Kumar being appointed as an Additional Director. Mr. Satish Mehta will take over as Chairman of the Company. The changes are effective from the conclusion of the ensuing Annual General Meeting.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, showing a strong all-round performance with increased revenue, EBITDA, and PAT. The company has also announced key leadership changes, including the appointment of Mr. Satish Mehta as Chairman and Mr. Samit Mehta as COO, and the elevation of Gennova Biopharmaceuticals to a wholly-owned subsidiary.